Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 752

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 752
---
, 2025, we issued warrants to purchase
up to an aggregate of 300,700 shares of common stock at an exercise price of $2.95 per share. The February 2025 Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance. We issued to the Placement Agent (or its designees) warrants to
purchase up to 22,554 shares of common stock. The February 2025 Placement Agent Warrants have an exercise price equal to $4.469 per share
and are exercisable upon issuance, or February 6, 2025, for twenty-four months from the date of issuance, or February 8, 2027.

The warrants described above were deemed exempt
from registration in reliance on Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of
securities were made to an accredited investor and did not involve a public offering. The recipients of such securities represented its
intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.

Option Grants

On July 16, 2024, the effective date of shareholder
approval to increase the number of shares authorized under the 2022 Plan, we granted a total of 504 fully vested, non-qualified options
to purchase shares of common stock at a per share exercise price of $318.00 to the following directors and in the amounts listed: (i)
Stephen Toovey (126 common stock options), (ii) Charles Allen (126 common stock options), (iii) Paul Field (126 common stock options)
and (iv) Cheryl Xu (126 common stock options).

42

On July 16, 2024, the effective date of shareholder
approval to increase the number of shares authorized under the 2022 Plan, we granted a total of 12,334 options to purchase shares of
common stock at a per share exercise price of $60.00 to Geoff Dow, our Chief Executive Officer, (5,000 common stock options), Tyrone
Miller, our Chief Financial Officer (4,000 common stock options), and Bryan Smith, an external consultant, (3,334 common stock options).
These options vest in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024.

On September 26, 2024, we granted 4,